The basic objective of this research project remains as it was i.e. to identify and characterize the neurotransmitter and neuromodulator systems which might have a role in regulating the dopamine (DA) system. The mesolimbic and mesocortical A 10 DA systems have been implicated in the pathophysiology of schizophrenia, the therapeutic action of antipsychotic drugs (APDs), and the action of drugs of abuse. Since numerous studies have shown that serotonin (5-hydroxytryptamine or 5-HT) exerts a modulatory action upon the DA system, we have begun to identify and characterize 5-HT receptor subtypes, by which 5-HT's modulatory action may be mediated. In this research application, we propose to continue our efforts toward characterizing the physiological and pharmacological properties of 5-HT3- like receptors. Emphasis will be put on the advancement in understanding the mechanism by which 5-HT3 receptor agonist suppress neuronal firing of cells in CA1 hippocampus and medial prefrontal cortex (mPFC) in in vitro brain slice preparations where cells can be recorded intracellularly and the external milieu better controlled. Furthermore, we shall continue our effort to elucidate where and how 5-HT3 receptor agonist and antagonists may interact with the DA systems and to examine underlying mechanisms by which chronic treatment with 5-HT3 receptor antagonists preferentially reduce the number of spontaneously active DA cells in the ventral tegmental area. Our preliminary results showed that 5-HT and 2-methyl-5-HT (a relatively selective 5-HT3 receptor agonist) potentiate the inhibitory action of DA on the firing of DA target neurons in the mPFc and nucleus accumbens but not in the caudate-putamen. Moreover, the modulatory effect of 5-HT and 2-methyl-5-HT on DA's action is primarily mediated by 5-HT3-like receptors. It is hypothesized that the ability of 5-HT3 receptor antagonists to block the potentiating action of 5-HT and 2-methyl-5-HT on the mesocorticolimbic DA system may account for, at least partly, their antipsychotic potential and perhaps their therapeutic potential for treating some aspect of drug abuse in humans. The techniques of in vivo extracellular single cell recording, microiontophoresis and intracellular electrode and whole cell patch recordings in in vitro slices will be used to systematically test this hypothesis. The results of the present proposal should help us to further elucidate the functional role of 5-HT3-like receptors in the brain and to understand where and how 5-HT and DA interact. Ultimately such knowledge should (1) contribute to the identification of neuronal systems which may be involved in the pathogenesis of schizophrenia and the drug abuse, and (2) lead to development of new types of APDs, or pharmacotherapy of drug addicts, with maximum therapeutic efficacy and minimum side effects.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH041440-09
Application #
2245169
Study Section
Neuropharmacology and Neurochemistry Review Committee (NPNC)
Project Start
1985-07-01
Project End
1999-06-30
Budget Start
1995-07-01
Budget End
1996-06-30
Support Year
9
Fiscal Year
1995
Total Cost
Indirect Cost
Name
State University New York Stony Brook
Department
Psychiatry
Type
Schools of Medicine
DUNS #
804878247
City
Stony Brook
State
NY
Country
United States
Zip Code
11794
Ninan, Ipe; Jardemark, Kent E; Liang, Xiaofu et al. (2003) Calcium/calmodulin-dependent kinase II is involved in the facilitating effect of clozapine on NMDA- and electrically evoked responses in the medial prefrontal cortical pyramidal cells. Synapse 47:285-94
Jardemark, K E; Ninan, I; Liang, X et al. (2003) Protein kinase C is involved in clozapine's facilitation of N-methyl-D-aspartate- and electrically evoked responses in pyramidal cells of the medial prefrontal cortex. Neuroscience 118:501-12
Ninan, Ipe; Wang, Rex Y (2003) Modulation of the ability of clozapine to facilitate NMDA- and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: pharmacological evidence. Eur J Neurosci 17:1306-12
Jardemark, K E; Liang, X; Arvanov, V et al. (2000) Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-aspartate. Neuroscience 100:9-Jan
Arvanov, V L; Wang, R Y (1999) Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J Pharmacol Exp Ther 289:1000-6
Arvanov, V L; Liang, X; Magro, P et al. (1999) A pre- and postsynaptic modulatory action of 5-HT and the 5-HT2A, 2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex. Eur J Neurosci 11:2917-34
Arvanov, V L; Liang, X; Russo, A et al. (1999) LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex. Eur J Neurosci 11:3064-72
Liang, X; Arvanov, V L; Wang, R Y (1998) Inhibition of NMDA-receptor mediated response in the rat medial prefrontal cortical pyramidal cells by the 5-HT3 receptor agonist SR 57227A and 5-HT: intracellular studies. Synapse 29:257-68
Wang, R Y; Liang, X (1998) M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology 19:74-85
Liang, X; Wang, R Y (1998) Biphasic modulatory action of the selective sigma receptor ligand SR 31742A on N-methyl-D-aspartate-induced neuronal responses in the frontal cortex. Brain Res 807:208-13

Showing the most recent 10 out of 60 publications